Core Insights - Thermo Fisher Scientific (TMO) reported quarterly earnings of $5.79 per share, exceeding the Zacks Consensus Estimate of $5.5 per share and up from $5.28 per share a year ago [1] - The company achieved revenues of $11.12 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.99% and increasing from $10.6 billion year-over-year [3] Earnings Performance - The earnings surprise for the quarter was +5.27%, with the company having surpassed consensus EPS estimates in all four of the last quarters [2] - The previous quarter's earnings were also above expectations, with actual earnings of $5.36 compared to an expected $5.22, resulting in a surprise of +2.68% [2] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $6.48, with expected revenues of $11.78 billion, and for the current fiscal year, the estimate is $22.50 on revenues of $43.92 billion [8] - The estimate revisions trend for Thermo Fisher was unfavorable prior to the earnings release, leading to a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [7] Industry Context - Thermo Fisher operates within the Zacks Medical - Instruments industry, which is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable industry backdrop [9] - The performance of Thermo Fisher's stock may be influenced by the overall outlook for the industry, as top-ranked industries tend to outperform lower-ranked ones significantly [9]

Company Overview - STRATA Skin Sciences, Inc. is a medical technology company focused on developing and commercializing products for dermatological conditions, utilizing expertise in laser technology [1] Financial Performance - STRATA's Return on Invested Capital (ROIC) is -58.59%, while its Weighted Average Cost of Capital (WACC) is 7.71%, resulting in a ROIC to WACC ratio of -7.60, indicating inefficiencies in capital utilization [2] - Comparatively, Sensus Healthcare, Inc. has a ROIC of -4.47% and a WACC of 10.28%, leading to a ROIC to WACC ratio of -0.44, which is the highest among its peers, suggesting better capital efficiency [3] - Other peers like Soleno Therapeutics, Inc. and SenesTech, Inc. have ROIC to WACC ratios of -13.40 and -12.05, respectively, indicating significant challenges in generating returns above their cost of capital [4] - Xcel Brands, Inc. also faces issues with a ROIC to WACC ratio of -8.94, highlighting inefficiencies in capital management [4] - Overall, all companies, including STRATA, are struggling to generate returns above their cost of capital, with Sensus Healthcare standing out for its relatively better performance [5]

Company Performance - Steris reported quarterly earnings of $2.34 per share, exceeding the Zacks Consensus Estimate of $2.32 per share, and up from $2.03 per share a year ago, representing an earnings surprise of +0.86% [1] - The company posted revenues of $1.39 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.36%, compared to $1.28 billion in the same quarter last year [2] - Over the last four quarters, Steris has surpassed consensus EPS estimates three times and topped consensus revenue estimates once [2] Future Outlook - The immediate price movement of Steris shares will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.39 on revenues of $1.41 billion, and for the current fiscal year, it is $10.12 on revenues of $5.83 billion [7] Industry Context - The Medical - Instruments industry, to which Steris belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Steris's stock performance [5][6]

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non- re ...

Sensus Healthcare, Inc. (SRTS) closed at $4.69 in the latest trading session, marking a +1.3% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 1.67%. On the other hand, the Dow registered a gain of 1.07%, and the technology-centric Nasdaq increased by 2.5%.Coming into today, shares of the company had lost 5.12% in the past month. In that same time, the Medical sector lost 9.34%, while the S&P 500 lost 6.57%.The upcoming earnings release of Sensus Healthcare, Inc. will ...

In the latest trading session, Sensus Healthcare, Inc. (SRTS) closed at $4.48, marking a +0.45% move from the previous day. This move outpaced the S&P 500's daily loss of 0.23%. Meanwhile, the Dow experienced a drop of 0.91%, and the technology-dominated Nasdaq saw an increase of 0.1%.The company's stock has dropped by 3.04% in the past month, exceeding the Medical sector's loss of 10.2% and the S&P 500's loss of 12.13%.Market participants will be closely following the financial results of Sensus Healthcare ...